Hemlibra ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
288自己免疫性後天性凝固因子欠乏症3

288. 自己免疫性後天性凝固因子欠乏症


臨床試験数 : 206 薬物数 : 231 - (DrugBank : 28) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 21
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04567511
(ClinicalTrials.gov)
September 1, 202129/7/2020Hemlibra in Mild Hemophilia AProspective, Single-Arm, Open-Label Use of Hemlibra (Emicizumab) in the Treatment of Mild Hemophilia AFactor VIII Deficiency, CongenitalDrug: EmicizumabIndiana Hemophilia &Thrombosis Center, Inc.Genentech, Inc.Recruiting5 Years45 YearsMale40Phase 4United States
2EUCTR2019-004430-42-AT
(EUCTR)
22/06/202122/04/2021Evaluation of the effect of emicizumab in patients suffering from acute bleeds with previously no family history.Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial Acquired Hemophilia A (AHA)
MedDRA version: 22.1;Level: LLT;Classification code 10053761;Term: Acquired hemophilia with anti FVIII, XI, or XIII;System Organ Class: 100000004851
MedDRA version: 20.0;Classification code 10053760;Term: Acquired hemophilia;System Organ Class: 100000004851;Therapeutic area: Body processes [G] - Immune system processes [G12]
Trade Name: Hemlibra®
INN or Proposed INN: Emicizumab
Other descriptive name: RO5534262 EMICIZUMAB
GWT-TUD GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
47Phase 2Austria;Germany
3EUCTR2019-004430-42-DE
(EUCTR)
25/01/202120/11/2020Evaluation of the effect of emicizumab in patients suffering from acute bleeds with previously no family history.Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial Acquired Hemophilia A (AHA)
MedDRA version: 22.1;Level: LLT;Classification code 10053761;Term: Acquired hemophilia with anti FVIII, XI, or XIII;System Organ Class: 100000004851
MedDRA version: 20.0;Classification code 10053760;Term: Acquired hemophilia;System Organ Class: 100000004851;Therapeutic area: Body processes [G] - Immune system processes [G12]
Trade Name: Hemlibra®
INN or Proposed INN: Emicizumab
Other descriptive name: RO5534262 EMICIZUMAB
GWT-TUD GmbHNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
47Phase 2Austria;Germany